Search Within

Martee L Hensley

  1. "Biostatistics Service"
Formats
  1. Journal Article (54)
  2. Meeting Abstract (27)
Groups
  1. Biostatistics Service (81)
  2. Department of Medicine (81)
  3. Epidemiology and Biostatistics (81)
  4. GDMT, Medicine (81)
  5. Gynecologic Medicine Service (81)
  6. Gynecology Disease Management Team (81)

More Groups

People
  1. Alexia Iasonos (52)
  2. Carol Aghajanian (46)
  3. Paul Sabbatini (38)
  4. David Spriggs (29)
  5. Qin Zhou (29)
  6. Jason Konner (22)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (5)
  5. 2021 (1)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (28)
  2. Gynecologic Oncology (21)
  3. International Journal of Gynecological Cancer (10)
  4. Cancer (5)
  5. Clinical Cancer Research (4)
  6. Cancer Immunology, Immunotherapy (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (29)
  2. Elsevier Inc. (23)
  3. Lippincott Williams & Wilkins (10)
  4. American Association for Cancer Research (5)
  5. Wiley Blackwell (5)
  6. Springer (2)

More Publishers

Results (81)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Journal Article

    Kahn, R. M.; Ragupathi, G.; Zhou, Q. C.; Iasonos, A.; Kravetz, S.; Hensley, M. L.; Konner, J. A.; Makker, V.; Tew, W. P.; Aghajanian, C.; more...
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
    Journal Article

    Crowley, F.; Cadoo, K. A.; Chiang, S.; Mandelker, D. L.; Bajwa, R.; Iasonos, A.; Zhou, Q. C.; Miller, K. M.; Hensley, M. L.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2022)

    Fulltext@MSK | Save